Calculate exact syringe units for the GLOW Blend (BPC-157 + TB-500 + GHK-Cu) pre-mixed blend. The dose shown is from the combined vial — no separate math needed.
Adjust vial, water, and dose — answer updates live
on a U-100 syringe for a 750mcg dose
Never miss a dose — 750mcg daily, draw 15.0 units on U-100 syringe.
No signup required to use calculator
Sync to any calendar app
Over 4,000 human genes respond to a single copper-binding tripeptide. That tripeptide is GHK-Cu, and the GLOW Blend builds an entire healing protocol around it. Full name: BPC-157 + TB-500 + GHK-Cu (also called the triple healing stack). No CAS number exists for the combination. BPC-157 upregulates VEGF to build new blood vessels at injury sites. It modulates nitric oxide for vascular protection and activates the FAK-paxillin pathway for tendon and ligament repair. TB-500 (the active fragment of Thymosin Beta-4) upregulates actin, a cell-building protein that moves repair cells to wound sites. It also drops pro-inflammatory cytokines across the entire body. GHK-Cu delivers copper ions to tissue, triggering collagen I and III synthesis and decorin expression for organized (not fibrotic) tissue remodeling. Community adoption sits at roughly 200+ Reddit threads and a 4.3/5 sentiment score. Users consistently describe higher-quality healed tissue compared to BPC-157 plus TB-500 alone, with less scar formation and visible skin improvements by week four. The primary complaint: budget pre-mixed vials deliver roughly 200 mcg of GHK-Cu, which is 5 to 10 times below the community-effective dose of 1 to 2 mg daily. The honest assessment: zero human combination trials exist. BPC-157 has one published human pilot (PMID 40131143, n=2, IV only). TB-500 has Phase I pharmacokinetic data only (PMC8419156). GHK-Cu evidence is primarily in vitro and animal. Promising preclinical data and strong community consensus, but the clinical gap is real.
